Peginterferon Alfa-2a in Patients with Chronic Hepatitis C and Cirrhosis

2000885 citationsJournal Articlebronze Open Access

Authors

E. Jenny Heathcote · University Health Network

Mitchell L. Shiffman · Virginia Commonwealth University Medical Center

W. Graham E. Cooksley · Royal Brisbane and Women's Hospital

Geoffrey Dusheiko · University College London

Samuel S. Lee · Heritage Medical Research Clinic

Luis A. Balart · Louisiana State University Health Sciences Center New Orleans

Robert Reindollar

Abstract

In patients with chronic hepatitis C and cirrhosis or bridging fibrosis, 180 microg of peginterferon alfa-2a administered once weekly is significantly more effective than 3 million units of standard interferon alfa-2a administered three times weekly.

Topics & Keywords

Hepatitis C virus research Liver Disease Diagnosis and Treatment Hepatitis B Virus Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 343, Issue 23, pp. 1673-1680

DOI: 10.1056/nejm200012073432302

Field-Weighted Citation Impact: 51.61